The RNAi therapeutics market is anticipated to grow at an annualized rate of more than 45%, till 2030, ByRoots Analysis
The RNAi therapeutics market is anticipated to grow at an annualized rate of more than 45%, till 2030, ByRoots Analysis Nov 25

The RNAi therapeutics market is anticipated to grow at an annualized rate of more than 45%, till 2030, ByRoots Analysis

days hours remaining

The recent approval of first RNAi therapeutic, ONPATTROTM, has caused a surge in interest of the industry / non-industry players in upcoming field of pharmacological research London

Roots Analysis has announced the addition of “RNAi Therapeutics Market (2nd Edition), 2019-2030” report to its list of offerings.

Significant advancements in the developmental pipeline across various oncological disorders, infectious diseases and genetic disorders have amplified the interest of various pharmaceutical establishments and have inspired research groups across the world, to focus their efforts on the development of RNAi therapeutics. Further, there are multiple pipeline candidates in mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years.

To order this 350+ page report, which features 130+ figures and 190+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market-2nd-edition-2019-2030/278.html

25-November-2021 - 16:30 Start date
28-November-2021 - 19:00 End date
united states
The RNAi therapeutics market is anticipated to grow at an annualized rate of more than 45%, till 2030, ByRoots Analysis has not posted anything yet